Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $130.00 at HC Wainwright

Mirum Pharmaceuticals (NASDAQ:MIRM) had its price target upped by HC Wainwright from $102.00 to $130.00 in a research report report published on Monday, Marketbeat.com reports. They currently have a buy rating on the stock.

MIRM has been the subject of several other research reports. TD Cowen reiterated a “buy” rating on shares of Mirum Pharmaceuticals in a report on Monday, January 12th. Wall Street Zen upgraded Mirum Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 17th. Stifel Nicolaus boosted their price target on Mirum Pharmaceuticals from $92.00 to $98.00 and gave the stock a “buy” rating in a research note on Tuesday, December 16th. Evercore ISI restated an “outperform” rating and set a $101.00 price objective on shares of Mirum Pharmaceuticals in a report on Tuesday, January 20th. Finally, Citigroup reiterated an “outperform” rating on shares of Mirum Pharmaceuticals in a research note on Friday, December 19th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $104.92.

Mirum Pharmaceuticals Stock Performance

MIRM stock opened at $96.92 on Monday. Mirum Pharmaceuticals has a one year low of $36.88 and a one year high of $98.49. The firm has a market cap of $4.98 billion, a price-to-earnings ratio of -112.70 and a beta of 0.48. The company has a debt-to-equity ratio of 1.06, a quick ratio of 3.16 and a current ratio of 3.31. The firm has a 50-day simple moving average of $77.82 and a two-hundred day simple moving average of $71.21.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings data on Tuesday, November 4th. The company reported $0.05 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.15. Mirum Pharmaceuticals had a negative net margin of 8.78% and a negative return on equity of 16.47%. The firm had revenue of $133.01 million during the quarter, compared to analyst estimates of $130.11 million. During the same quarter in the previous year, the business posted ($0.30) EPS. Mirum Pharmaceuticals’s revenue was up 47.1% on a year-over-year basis. On average, equities analysts forecast that Mirum Pharmaceuticals will post -1.43 EPS for the current fiscal year.

Insider Buying and Selling

In related news, COO Peter Radovich sold 2,382 shares of the firm’s stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $93.33, for a total transaction of $222,312.06. Following the completion of the transaction, the chief operating officer owned 20,679 shares of the company’s stock, valued at $1,929,971.07. This trade represents a 10.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Christopher Peetz sold 7,098 shares of the business’s stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $93.33, for a total transaction of $662,456.34. Following the transaction, the chief executive officer owned 163,733 shares of the company’s stock, valued at $15,281,200.89. This represents a 4.15% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 20,560 shares of company stock worth $1,897,717 in the last quarter. 22.87% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the stock. Wellington Management Group LLP boosted its stake in shares of Mirum Pharmaceuticals by 566.8% in the third quarter. Wellington Management Group LLP now owns 790,689 shares of the company’s stock worth $57,965,000 after buying an additional 672,118 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in Mirum Pharmaceuticals by 709.5% in the third quarter. Arrowstreet Capital Limited Partnership now owns 612,318 shares of the company’s stock valued at $44,889,000 after acquiring an additional 536,674 shares during the period. Voloridge Investment Management LLC boosted its position in Mirum Pharmaceuticals by 2,116.6% in the 3rd quarter. Voloridge Investment Management LLC now owns 389,574 shares of the company’s stock worth $28,560,000 after purchasing an additional 371,999 shares in the last quarter. Balyasny Asset Management L.P. purchased a new stake in Mirum Pharmaceuticals in the 3rd quarter worth approximately $23,250,000. Finally, William Blair Investment Management LLC acquired a new stake in shares of Mirum Pharmaceuticals during the 3rd quarter worth approximately $22,965,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.